Amgen Inc. (NASDAQ:AMGN) Stake Reduced by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 20.1% in the first quarter, according to its most recent filing with the SEC. The firm owned 593,039 shares of the medical research company's stock after selling 148,746 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.11% of Amgen worth $184,761,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Capital World Investors grew its stake in Amgen by 1,292.0% in the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock valued at $1,693,042,000 after buying an additional 6,029,058 shares during the last quarter. Norges Bank bought a new position in Amgen during the 4th quarter worth $1,541,991,000. GAMMA Investing LLC grew its stake in Amgen by 43,573.5% during the first quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company's stock worth $1,140,768,000 after buying an additional 3,653,205 shares in the last quarter. Capital International Investors raised its position in Amgen by 40.1% during the fourth quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock valued at $3,182,843,000 after purchasing an additional 3,495,503 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in Amgen by 52.7% in the fourth quarter. Franklin Resources Inc. now owns 3,291,975 shares of the medical research company's stock valued at $858,020,000 after buying an additional 1,135,884 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the transaction, the senior vice president directly owned 8,162 shares in the company, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.69% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Mizuho boosted their target price on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research note on Wednesday, May 7th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $305.00 price objective on shares of Amgen in a research note on Tuesday, June 24th. William Blair reiterated an "outperform" rating on shares of Amgen in a research report on Tuesday, June 24th. Citigroup upped their target price on Amgen from $300.00 to $305.00 and gave the stock a "neutral" rating in a research note on Tuesday. Finally, Piper Sandler reiterated an "overweight" rating and set a $328.00 price target on shares of Amgen in a research report on Friday, June 27th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $308.77.

Amgen Stock Performance

Shares of Amgen stock traded up $9.82 on Tuesday, hitting $305.69. The stock had a trading volume of 2,520,306 shares, compared to its average volume of 2,842,800. The company's 50 day moving average price is $285.90 and its 200 day moving average price is $289.56. The stock has a market cap of $164.37 billion, a price-to-earnings ratio of 27.89, a P/E/G ratio of 2.67 and a beta of 0.49. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same quarter in the previous year, the company earned $3.96 EPS. The company's quarterly revenue was up 9.4% on a year-over-year basis. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.